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Abstract
Background: We evaluated possible diagnostic and prognostic values of serum midkine in malignant pleural
mesothelioma in comparison with those of serum mesothelin, a well-established diagnostic biomarker.
Methods: Serum mesothelin and midkine levels were determined with an enzyme-linked immunosorbent assay. We
examined specimens from 95 Turkish cases with malignant pleural mesothelioma, 56 metastatic cancers to pleura, 27
other types of benign pleural diseases and 20 benign asbestos pleurisy. The cut-off values were 1.5 nmol/L for
mesothelin and 421 pg/mL for midkine.
Results: Sensitivity and specificity of mesothelin were 51.6 and 71.4%, 51.6 and 85.2%, and 51.6 and 85% for
differentiating mesothelioma from metastatic cancers to pleura, other benign pleural diseases and benign
asbestos pleurisy, respectively. Sensitivity and specificity of midkine were 61.1 and 41.1%, 61.1 and 48.1%, and
61.1 and 75% to distinguish mesothelioma from metastatic cancers to pleura, other benign pleural diseases
and benign asbestos pleurisy, respectively. Combination of both biomarkers did not improve the differential
diagnostic efficacy. Mesothelin levels were elevated in the epitheloid type and in the advanced cases, but
were not related to the prognosis. In contrast, elevated baseline levels of midkine were independently
associated with a poor prognosis of mesothelioma patients after adjusting for the stage, the histological
subtypes and treatment schedules (HR = 1.84; 95% CI: 1.09-3.09) (p = 0.022).
Conclusions: Serum mesothelin showed moderate sensitivity and high specificity to differentiate malignant
pleural mesothelioma from metastatic malignancy to pleura and from benign pleural diseases. In contrast,
midkine was a useful marker for predicting prognosis of mesothelioma patients.
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Background
Malignant pleural mesothelioma is an aggressive tumor
with poor prognosis and remains a worldwide health
problem. The diagnosis of mesothelioma is based on an
immunohistochemical staining of pleural tissues obtained
from biopsy [1]. Nevertheless, differentiation between
mesothelioma and other pleural diseases is difficult in
some cases even with the staining of biopsy specimens. In
addition, there are not clinical and laboratory markers
available which can predict prognosis of the patients.
Development of such relevant markers is desirable not
only for precise diagnosis but also for improving the treat-
ment protocol. A less invasive method for collecting
clinical specimens is also favorable for senior patients as
are often found in mesothelioma.
Previous studies used serum and pleural effusions to
search possible markers for diagnosis and prognosis of
mesothelioma. Potential biomarkers that had been inves-
tigated included mesothelin [2–4], megakaryocyte-
potentiating factor [5], osteopontin [6, 7], hyaluronan
[8], syndecan [9], galectin-1 [10] and fibulin-3 [3, 11].
These biomarkers have moderate sensitivity but high
specificity to differentiate mesothelioma from other
pleural diseases. Two previous meta-analyses, for ex-
ample, reported that both mesothelin and osteopontin
showed 61 and 57% for the sensitivity and 87 and 81%
for the specificity to differential diagnose mesothelioma
from others, respectively [4, 7]. These are currently in
use as positive diagnostic markers for mesothelioma in
clinical fields. Nevertheless, negative results of these
markers are not sufficient to exclude possibility of meso-
thelioma, and the positive results even need further
validation with different diagnostic procedures. Subse-
quent studies also demonstrated that some of the above
biomarkers could be related to the prognosis of meso-
thelioma [9, 10, 12, 13], but the value to predict the
prognosis was limited.
There is not currently a reliable blood-based bio-
marker available as for diagnosis and prognosis of meso-
thelioma except serum mesothelin. Mesothelioma is one
of the intractable cancers and is often resistant to
chemotherapy. A good prognostic marker is thereby
beneficial for the patients to select treatment options
and furthermore, patient groupings based on such a
marker will contribute to possible clinical studies that
investigate efficacy of a therapeutic agent. Midkine is a
heparin-binding growth factor that promotes survival,
growth and migration of cells [14]. It is prominently
expressed during embryogenesis, especially in the mid-
gestation period, but is down-regulated to an insignifi-
cant level in healthy adults [15]. Overexpression of
midkine has however been observed in various patho-
logical conditions including cancer [16]. Midkine seems
to play a crucial role in carcinogenesis and is markedly
up-regulated in numerous types of malignancy [14].
Moreover, the midkine level can be correlated with a
dim prognosis of several cancers [17, 18], but it has not
yet been evaluated in mesothelioma. We investigated in
the present study to compare mesothelin, a well-
established biomarker for mesothelioma, with midkine, a
possible novel marker, in the diagnosis and the prognosis
of malignant pleural mesothelioma.
Methods
Patients and samples
A total of 198 patients who were diagnosed and treated in
Eskisehir Osmangazi University Hospital, Turkey, were
enrolled in this study. Three groups of patients included
in the study were as follows: 95 patients with malignant
pleural mesothelioma; 56 patients with metastatic cancers
to pleura; 47 patients with benign pleural diseases includ-
ing 20 with benign asbestos pleurisy and 27 with other be-
nign pleural diseases. None of the patients had received
chemotherapy, surgical treatments or radiotherapy prior
to the diagnosis. Clinical data, including age, gender, hist-
ology, stage, treatment history, response to chemotherapy
and survival characteristics, were collected for all the
mesothelioma and other patients. All the procedures in-
volving human participants were performed in accordance
with the ethical standards of relevant committees in
Eskisehir Osmangazi University, and with the 1964
Helsinki declaration and the amendments approved in
Fortaleza, 2013. The local ethical committee of Eskisehir
Osmangazi University approved the study, and all of the
patients provided a written informed consent for analysis
of biomarkers in their sera. The ethical committee of
Chiba Cancer Center and Toho University also approved
the study.
The diagnosis of mesothelioma and other cancers was
confirmed with immunohistochemical staining. Benign
asbestos pleurisy was diagnosed with a pathological ana-
lysis of pleural biopsy, a history of asbestos exposure and
exclusion of the other causes of pleurisy, together with a
3-year observation period to eliminate possible malig-
nancy. Other benign diseases included were tuberculosis,
pulmonary embolism, congestive heart failure, hepatic
hydrothorax, rheumatoid pleurisy, cholesterol pleural effu-
sion, chronic renal failure, pneumoconiosis and parapneu-
monic pleurisy. These were diagnosed with a number of
clinical characteristics and the histological analysis. The
mesothelioma patients were staged according to the Inter-
national Mesothelioma Interest Group staging system
[19]. The response to the first-line chemotherapy, combin-
ation of cisplatin and pemetrexed, was evaluated using a
modified response evaluation criteria in solid tumors
(RECIST) [20].
Blood samples were sourced from the tissue bank of
the Lung and Pleural Cancer Research and Clinical
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Center of Eskisehir Osmangazi University. The speci-
mens were collected prospectively from the patients and
stored at −80 °C.
Assay for mesothelin and midkine
Serum mesothelin levels were determined with a chemilu-
minescent enzyme immunoassay using an anti-soluble
mesothelin related peptide antibody (Fujirebio, Tokyo,
Japan), and serum midkine concentrations were deter-
mined with an enzyme-linked immunosorbent assay using
an anti-midkine antibody (Cellmid, Sydney, Australia), ac-
cording to the manufacturers’ instructions. The assays
were performed in an independent manner from the clin-
ical data. Cut-off values for mesothelin and midkine were
1.5 nmol/L and 421 pg/mL, respectively. The cut-off value
of serum midkine concentration, mean plus 2 times stand-
ard deviations (SD), was determined with data from
Cellmid, which were based on 99 healthy blood donors. A
concentration below 103.95 pg/mL was undetectable with
the midkine assay.
Statistical analysis
Data were analyzed using a statistical software (SPSS for
windows, Version 15.0). Results were expressed as the
mean value ± SD or median. The Kolmogorov-Simirnov
test was used to assess distribution differences of the
samples. Mann-Whitney U and Kruskal Wallis tests
were used to compare 2 and more than 2 groups, re-
spectively, since biomarker levels did not show normal
distributions. Bonferroni correction was also used to
determine difference of respective groups. Receiver
operating characteristic (ROC) curve analysis was con-
ducted to determine predictive values for mesothelin
and midkine at differentiating mesothelioma from other
pleural diseases. The area under the curve (AUC) and
SD were also estimated. Predictive values were com-
pared with the method of DeLong et al. [21]. The nat-
ural logarithm of biomarkers was used to compare
predictive powers of the markers in combination, and
then standardization of the markers was performed. The
weight value of each marker was determined with the lo-
gistic regression analysis. Each marker was multiplied by
the logistic regression coefficient, and the results were
added to the combined marker values. The AUC, cut-off
values and predictive values of new variables were then
estimated. The median survival times and 95% confi-
dence intervals (CI) were estimated for each mesotheli-
oma group. The survival curves were generated with the
Kaplan-Meier method. The median survival time be-
tween the groups was compared with the log-rank test.
The Cox proportional hazards regression test was used
to access effects of potential prognostic factors on sur-
vival. The survival was adjusted by several prognostic
factors including the clinical stage, histological subtypes
and treatment schedules.
Results
Patient profiles and serum biomarker levels
The profiles of the patients who were examined for
serum concentrations of mesothelin and midkine were
summarized in Table 1. Most of patients were from an
area in Turkey where people were exposed to environ-
mental asbestos, which made gender distribution of the
patients almost equal. A majority of histological types in
mesothelioma was epitheloid followed by mixed (bi-
phasic) and sarcomatoid. We assayed 198 cases in total
Table 1 Patient profiles
Patient numbers (%) Age average ± SD (min-max in year) Gender Male/Female
Malignant mesothelioma 95 (48.0) 63.0 ± 11.0 (26-86) 49/46
Epitheloid 66 (69.5)
Mixed (Biphasic) 15 (15.8)
Sarcomatoid 8 (8.4)
Undefined 6 (6.3)
Metastatic cancers to pleura 56 (28.3) 61.6 ± 11.2 (34-85) 32/24
Lung cancer 38 (67.9) 62.2 ± 11.9 (34-85) 27/11
Other type of cancera 18 (32.1) 60.4 ± 9.7 (39-77) 5/13
Non-malignant pleural diseases 47 (23.7) 55.8 ± 17.0 (19-81) 36/11
Benign asbestos pleurisy 20 (42.6) 61.7 ± 12.9 (40-81) 17/3
Benign pleural diseasesb 27 (57.4) 51.4 ± 18.6 (19-77) 19/8
Total 198
aincluding 8 cases of breast cancers, 3 lymphomas, 2 ovarian cancers, 1 stomach cancer, 1 renal cell carcinoma, 1 bladder cancer, 1 pancreatic cancer, 1
laryngeal cancer
bincluding 17 cases of tuberculous pleurisies, 2 pulmonary embolisms, 2 congestive heart failures, 1 hepatic hydrothorax, 1 rheumatoid pleurisy, 1 cholesterol
pleural effusion, 1 chronic renal failure, 1 pneumoconiosis, 1 parapneumonic pleurisy
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for the serum mesothelin and midkine concentrations,
which included mesothelioma, metastatic cases to
pleura, and benign diseases with and without asbestos
pleurisy (Table 2). Serum mesothelin levels were signifi-
cantly higher in the patients with mesothelioma than in
those with metastatic cancers to pleura, benign asbestos
pleurisy, benign pleural diseases or pleural diseases other
than mesothelioma (Fig. 1a, Table 2). In contrast, serum
midkine levels of mesothelioma patients were not differ-
ent from those of patients with metastatic cancers to
pleura, benign pleural diseases or pleural diseases other
than mesothelioma, but were greater than those with
benign asbestos pleurisy patients. (Fig. 1b, Table 2).
Mesothelin therefore differentiated mesothelioma from
non-mesothelioma diseases, but midkine had a limited
value only to discriminate mesothelioma from benign
asbestos pleurisy. Nevertheless, differential diagnosis
between mesothelioma and benign asbestos pleurisy is
quite important in clinical settings.
Diagnostic ability of serum biomarkers
We further investigated possible diagnostic values of
mesothelin and midkine using ROC curve analyses to dif-
ferentiate mesothelioma from non-mesothelioma patients
(Fig. 2). The AUC of serum mesothelin to distinguish pa-
tients with mesothelioma from those with metastatic can-
cers to pleura was significantly higher than that of serum
midkine (p = 0.0330) but was not different from that of
combination of both mesothelin and midkine (p = 0.0738)
(Fig. 2a). The AUC of serum midkine for differentiating
mesothelioma from metastatic cancers to pleura was not
different from that of the combination of the two markers
(p = 0.3351). The AUC of serum mesothelin to distinguish
patients with mesothelioma from those with benign asbes-
tos pleurisy was not different from that of serum midkine
(p = 0.1641) or that of the combination of the two bio-
markers (p = 0.1055) (Fig. 2b). Nevertheless, the AUC of
combined serum mesothelin and midkine to distinguish
mesothelioma patients from benign asbestos pleurisy pa-
tients was significantly higher than that of midkine
(p = 0.0329). The AUC of serum mesothelin to distinguish
patients with mesothelioma from those with benign
pleural diseases was significantly higher than that of
midkine and the combination of the two biomarkers
(p = 0.0576 and p = 0.0115, respectively) (Fig. 2c). The
AUC of serum midkine to distinguish mesothelioma pa-
tients from benign patients with pleural diseases was not
different from that of the combination of the two markers
(p = 0.2476). The AUC of serum mesothelin to distinguish
patients with mesothelioma from those with all the other
diseases, including metastatic cancers, benign asbestos
pleurisy and benign pleural diseases, was higher than that
of midkine (p < 0.0001), whereas it was not different from
that of the combination of the two biomarkers
(p = 0.5598) (Fig. 2d). The AUC of the combination of the
biomarkers was higher than that of midkine to distinguish
patients with mesothelioma from all other patients in the
study (p = 0.0002).
We also examined the sensitivity, specificity, positive
and negative predictive values of mesothelin, midkine,
and the combination of the biomarkers to differentiate
patients of mesothelioma from other patients (Table 3).
The sensitivity of midkine was higher than that of
mesothelin, whereas the specificity of mesothelin was
greater than that of midkine. The combination of both
mesothelin and midkine showed a higher sensitivity than
mesothelin or midkine alone, but specificity of the com-
bination was similar to that of midkine except compari-
son of mesothelioma versus benign pleural diseases. The
combinatory use of both markers thus had a limited
diagnostic value compared with individual markers.
In addition, we evaluated possible utility of mesothelin
and midkine to discriminate early-staged mesothelioma
(stage I - II) from benign asbestos pleurisy since the dif-
ferential diagnosis between the two diseases is clinically
important. The AUCs of serum mesothelin and midkine
to distinguish patients with the early-staged mesotheli-
oma from patients with benign asbestos pleurisy were
0.655 (0.490-0.796), with a sensitivity of 42.9% and a
specificity of 85%, and 0.557 (0.394-0.712), with a sensi-
tivity of 33.3% and a specificity of 95.0%, respectively.
Both of the markers could thus not discriminate early-
staged mesothelioma from benign asbestos pleurisy
(mesothelin; p = 0.0736, midkine p = 0.534).
Clinical values of mesothelin and midkine in
mesothelioma
We classified the serum marker levels of mesothelioma
patients according to the stage, the histology and re-
sponses to chemotherapy (Table 4). Serum mesothelin
levels tended to increase with the stage advancement
(p = 0.052) and were higher in the epitheloid type than
the other non-epitheloid types, which included mixed
and sarcomatoid type, in histopathological classification
(p = 0.033). Serum midkine levels also tended to in-
crease according to the stage progress (P = 0.059), but
the levels were not related to the histological types of





Malignant mesothelioma 1.50 (0.30-67.50) 656.04 (103.95-17,381.64)
Metastatic cancers to pleura 0.90 (0.10-9.70) 560.69 (103.95-35,742.24)
Benign asbestos pleurisy 0.85 (0.10-3.40) 538.06 (103.95-1217.00)
Benign pleural diseases 0.80 (0.30-67.50) 423.03 (106.25-37,459.76)
Pleural diseases other than
malignant mesotheliomaa
0.80 (0.10-9.70) 423.03 (103.95-37,459.76)
aPleural diseases other than malignant mesothelioma include metastatic cancers,
benign asbestos pleurisy and benign pleural diseases
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mesothelioma (P = 0.501). Responses to chemotherapy
judged with modified RECIST was evaluated with 45 out
of 51 patients who received cisplatin plus pemetrexed-
based chemotherapy, which included 16 patients (35.6%)
with progressive disease, 17 patients (37.8%) with stable
disease and 12 patients (26.7%) with objective response.
Baseline serum mesothelin and midkine levels at the
diagnosis were not related to the chemotherapy re-
sponses of mesothelioma patients.
We then investigated possible prognostic values of serum
mesothelin and midkine in patients with mesothelioma
(Fig. 3). The survival was adjusted according to the clinical
stage, histological subtypes and treatment schedules. Serum
mesothelin levels were not related to median survival of pa-
tients with mesothelioma (p = 0.541) (Fig. 3a). In contrast,
high serum midkine levels were independently associated
with poor prognosis in mesothelioma (HR = 1.84; 95% CI:
1.09-3.09) (p = 0.022). The median survival time from diag-
nosis to death or the last day of follow-up with a 95% CI
was 13.7 ± 1.2 months (95% CI: 11.33-16.13) for patients
with serum midkine levels less than 421 pg/ml and was
8.4 ± 0.9 months (95% CI: 6.50-10.36) for those with serum
Fig. 2 Receiver operating characteristic curve of serum biomarkers. The curve showed ability of mesothelin, midkine or the combination to
differentiate between malignant mesothelioma and a metastatic cancers to pleura, b benign asbestos pleurisy, c benign pleural disease or
d pleural diseases other than mesothelioma that include metastatic cancers, benign asbestos pleurisy and benign pleural diseases
Fig. 1 Serum concentrations of mesothelin (a) and midkine (b) in various diseases. Pleural diseases other than mesothelioma (shown in Table 2)
are not included. Box plot with maximum and minimum values and the cut-off values (dotted line, mesothelin: 1.5 nmol/L, midkine; 421 pg/mL)
are indicated. Statistical analysis was conducted with Kruskal Wallis tests
Ak et al. BMC Cancer  (2017) 17:212 Page 5 of 10
midkine levels above 421 pg/ml (log-rank = 8.687;
p = 0.003) (Fig. 3b). We did not notice any difference of the
survival period between male patients, 10.1 ± 1.5 months
(7.1-13.04), and female patients, 9.6 ± 1.7 months (6.28-
12.99) (log-rank = 0.037; p = 0.847) in this study.
Discussion
Mesothelin was regarded as a biomarker for differential
diagnosis of mesothelioma [2–5, 12, 13, 22, 23]. In con-
trast, midkine has not yet been studied for a potential
role in either the diagnosis or the prognosis of meso-
thelioma. In the current study, we compared the diag-
nostic ability of mesothelin and midkine to differentiate
mesothelioma from other pleural disease, and we firstly
demonstrated to our knowledge that serum midkine
levels possessed a prognostic value in mesothelioma.
An initial study about mesothelin reported that an
elevated serum concentration was indicative of meso-
thelioma with a sensitivity of 84% and a specificity of
100% in comparison with other pleural diseases and
non-mesothelioma malignancy [2]. Subsequent studies
however suggested that sensitivity and specificity of
mesothelin in reference to various types of pleural dis-
eases and lung cancer was not as great as reported in
the initial study [3, 5]. A recent meta-analysis on serum
mesothelin showed that the sensitivity and the specificity
Table 3 Sensitivity, specificity, positive and negative predictive values of mesothelin and midkine in differentiating malignant




vs benign asbestos pleurisy
Malignant mesothelioma
vs benign pleural diseases
Malignant mesothelioma vs
Pleural diseases other than
malignant mesothelioma
Mesothelin
AUC (95% CI) 0.68 (0.60-0.75) 0.78 (0.69-0.85) 0.73 (0.64-0.81) 0.71 (0.64-0.77)
Sensitivity (%) (95% CI) 51.6 (43.6-59.6) 51.6 (42.5-60.7) 51.6 (42.7-60.5) 51.6 (44.6-58.6)
Specificity (%) (95% CI) 71.4 (64.2-78.6) 85.0 (78.5-91.5) 85.2 (78.9-91.5) 77.7 (71.9-83.5)
PPV (%) (95% CI) 75.4 (68.5-82.2) 94.2 (89.9-98.5) 92.5 (87.8-97.2) 68.1 (61.6-74.6)
NPV (%) (95% CI) 46.5 (38.5-54.5) 27.0 (18.9-35.1) 33.3 (24.9-41.7) 63.5 (56.8-70.2)
Midkine
AUC (95% CI) 0.52 (0.44-0.60) 0.69 (0.60-0.78) 0.54 (0.44-0.63) 0.52 (0.45-0.59)
Sensitivity (%) (95% CI) 61.1 (53.3-68.9) 61.1 (52.2-70.0) 61.1 (52.5-69.8) 61.1 (54.3-67.9)
Specificity (%) (95% CI) 41.1 (33.3-48.9) 75.0 (67.1-82.9) 48.1 (39.3-57.0) 49.5 (42.5-56.5)
PPV (%) (95% CI) 63.7 (58.0-71.4) 92.1 (87.2-97.0) 80.6 (73.6-87.6) 52.7 (45.7-60.0)
NPV (%) (95% CI) 38.3 (30.5-46.1) 28.8 (20.5-37.1) 26.0 (18.2-33.8) 58.0 (51.1-64.9)
Mesothelin + Midkine
AUC (95% CI) 0.59 (0.51-0.67) 0.83 (0.75-0.90) 0.65 (0.56-0.74) 0.73 (0.66-0.79)
Sensitivity (%) (95% CI) 88.4 (80.2-94.1) 88.42 (80.2-94.1) 100.0 (96.2-100.0) 80.0 (70.5-87.5)
Specificity (%) (95% CI) 32.7 (20.7-46.7) 77.78 (52.4-93.6) 0 (0.0-12.8) 58.8 (48.6-68.5)
PPV (%) (95% CI) 69.4 (60.4-77.5) 95.5 (88.7-98.8) 77.9 (69.5-84.9) 64.4 (55.1-73.0)
NPV (%) (95% CI) 62.1 (42.3-79.3) 56.0 (34.9-75.6) 0 (0-0) 75.9 (65.0-84.9)
AUC area under the curve, PPV positive predictive value, NPV negative predictive value
Table 4 Serum biomarker levels of patients with malignant







I (12) 0.95 (0.30-67.50) 220.54 (103.95-5508.08)
II (11) 1.20 (0.30-2.80) 513.61 (103.95-2143.51)
III (34) 1.25 (0.40-21.50) 644.89 (103.95-17,381.64)
IV (36) 2.90 (0.30-27.40) 925.17 (103.95-5244.74)
p = 0.052 p = 0.059
Histology (case number)
Epitheloid (66) 2.00 (0.30-67.50) 623.56 (103.95-17,381.64)
Non-epitheloid (23) 1.20 (0.30-9.0) 753.50(103.95-5244.74)
Undefined (6)b 1.25 (0.60-7.40) 768.13 (103.95-1722.46)
p = 0.033 p = 0.501
Chemotherapy response (case number)
Progressive disease (16) 1.75 (0.30-67.50) 731.47 (103.95-5508.08)
Stable disease (17) 1.70 (0.40-7.70) 417.94 (103.95-2832.48)
Objective response (12) 2.70 (0.70-21.50) 441.06 (103.95-17,381.64)
p = 0.452 p = 0.669
aTwo patients were not staged and excluded; bNot analyzed because of
insufficient case numbers
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were 61 and 87%, respectively, when compared with
various non-mesothelioma diseases [4]. In this study, we
demonstrated that mesothelin levels in mesothelioma
were greater than other pleural diseases when the serum
concentrations was compared with respective diseases or
the combination of all the diseases. The sensitivity and
the specificity data in this study were consistent with
previous studies [3, 5, 13, 22]. Other studies compared
different kinds of biomarkers with mesothelin in terms
of the diagnostic performance [3, 5, 12, 22, 23]. These
markers, including megakaryocyte potentiating factor,
fibulin-3, osteopontin, CA125 and hyaluronic acid, were
not as accurate as mesothelin to differentiate mesotheli-
oma from various non-mesothelioma diseases. We there-
fore evaluated midkine in the present study as a possible
new marker for differential diagnosis. Sensitivity of mid-
kine was comparable to or slightly greater than that of
mesothelin, but specificity of midkine was lower than that
of mesothelin. Midkine thus had less advantages than
mesothelin as a diagnostic marker like other above-
mentioned non-mesothelin markers except showing good
specificity in differentiation from benign asbestos pleurisy.
We however presume that a possible combinatory use of
the non-mesothelin markers including midkine might
attain a similar diagnostic level of mesothelin and such in-
vestigation needs to be conducted in future. Interestingly,
Ostroff et al. screened more than 1000 serum proteins
from mesothelioma patients and asbestos-exposed peoples
with a proteomic assay, and listed midkine as one of the
13 markers in a panel that was useful for differential diag-
nosis of mesothelioma from others [24]. The study did not
however show detailed data of midkine by itself in term of
the diagnostic and prognostic values and the present study
in fact firstly delineated the value of midkine as a bio-
marker in mesothelioma.
Detection of mesothelioma at an early stage is clinically
important. A majority of mesothelioma patients however
are diagnosed at an advanced stage and have poor progno-
sis with limited therapeutic efficacy. In clinical settings,
most cases being suspected of mesothelioma can be
diagnosed with a histological examination of pleural
specimens. Differential diagnosis of mesothelioma from
metastatic cancers to pleura and tuberculosis is not prob-
lematic, but benign asbestos pleurisy is the clinical entity
that needs to be differentiated from an early-staged meso-
thelioma. In fact, mesothelioma at an early phase were
sometimes diagnosed as benign asbestos pleurisy because
the benign diseases are also associated with a history of as-
bestos exposure and the specimens showed non-specific
immunohistochemical reactions. Consequently, a marker
to differentiate between the two kinds of diseases is valu-
able for patients with either disease. A meta-analysis study
dealing with respective patient data searched a possible
merit of serum mesothelin in the diagnosis [25], which in-
cluded more than 200 patients with stages I and II meso-
thelioma and 1600 symptomatic or high-risk controls. The
results indicated that mesothelin showed a sensitivity of
32% at 95% specificity and furthermore about 70% of
mesothelioma patients at the early stage were judged as
negative for mesothelin. The poor sensitivity of mesothelin
thus had a limited value for early diagnosis of mesotheli-
oma. Our results also indicated that neither serum
mesothelin or midkine discriminated mesothelioma at
stage I or II from benign asbestos pleurisy. In contrast, a
panel with 13 kinds of marker proteins which did not in-
clude mesothelin detected stage I and II mesothelioma
with a sensitivity of 88% under 92% accuracy [24]. The
data suggest that a combination of the markers, irrespect-
ive of whether mesothelin is included, can be useful for
differential diagnosis at the early stage.
There are contradictory studies on mesothelin expression
levels in different histological types and stages. A positive
rate of mesothelin were greater in epitheloid type than in
other types, and the mesothelin expressions increased ac-
cording to advanced stage diseases [2], whereas other stud-
ies showed that mesothelin levels were not related to the
histological type or stage of mesothelioma [3, 5, 12, 13].
The present study demonstrated that mesothelin levels
Fig. 3 Kaplan-Meier survival curves of patients of mesothelioma. Survival of the patients classified by a mesothelin levels at 1,5 nmol/L and b serum
midkine levels at 421 pg/mL
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preferentially elevated in epitheloid type compared with
non-epitheloid type, and relatively increased with the ad-
vanced cases. In contrast, midkine levels were not different
among the histological types, but they were associated with
advanced staging with marginal statistical significance.
Several studies showed that mesothelin served as a
marker for disease courses and for responses to the treat-
ments [2, 26–28]. These studies indicated that increased
serum levels of mesothelin were associated with disease
progression and unresponsiveness to chemotherapy. Linch
et al. however demonstrated that the mesothelin levels be-
fore chemotherapy did not correlate with the responses
[29]. We examined the relationship between baseline
levels of all the evaluable cases and their chemotherapy re-
sponses, and found that the levels of both mesothelin and
midkine markers were not associated with the responses.
The present results however needed careful evaluations
since sensitivity to chemotherapy was different among the
histological types and the clinical stages. We presume that
a possible relationship between biomarker levels and
chemotherapy responses should be examined in a pro-
spective and a chronological manner. Previous studies also
investigated any possible associations between baseline
mesothelin levels and the prognosis of mesothelioma pa-
tients, and demonstrated that the mesothelin levels did
not predict the prognosis [3, 28–30] although the tumor
volume changes after chemotherapy were well correlated
with mesothelin levels [31]. Other studies however re-
ported contradictory results that an elevated mesothe-
lin level was a poor prognostic factor in mesothelioma
[12, 13]. In the current study, we demonstrated that
mesothelin levels were not a predictive marker of the
prognosis, whereas elevated midkine levels were linked
to a poor prognosis. Other markers were also examined
as for the prognostic values in mesothelioma patients,
but osteopontin [12], hyaluronic acid [30] or fibulin-3
[3] were not a prognostic factor. In contrast, Hollevoet
et al. showed that low baseline osteopontin was related
with a favorable prognosis [28]. Treatment outcomes
are influenced by many factors, which are not limited
to histological types, clinical stages or performance sta-
tus, and moreover these factors are often reciprocally
associated with each other. These discrepant results
about the prognostic values can thereby be derived
from how these clinical parameters were analyzed.
Midkine expression in tumors was associated with cell
proliferation because the transcriptional activity was
dependent on cell growth and down-regulation of the
expression decreased tumor cell growth [32, 33]. We
showed that midkine was expressed in human meso-
thelioma cell lines (data not shown), but have not yet
analyzed midkine levels in the specimens because pre-
cise estimation of tumor ratios in respective clinical
samples is required. Relative low specificity of midkine
as a marker is associated with lack of tumor type specificity
of the midkine expression, and the elevated levels in
metastatic cancers to pleura are attributable to the
growth-linked property. Midkine expression is also
linked to inflammatory reactions, which can contribute
to elevated midkine levels in non-tumorous pleural dis-
eases. Nevertheless, midkine levels were not elevated in
benign asbestos pleurisy, in which inflammation was
not probably involved. These data rather suggests that
midkine is a negative maker to exclude benign asbestos
pleurisy which must be differentiated from other
pleural diseases including mesothelioma in clinical set-
tings. In addition, these data collectively indicated that
midkine was rather cell growth-related in contrast with
mesothelin which is relatively tissue-specific.
We showed that a baseline midkine level had a prog-
nostic value and the elevation was linked with poor
prognosis. A few recent studies indicated that elevated
midkine expression, assayed with immunohistochemistry
or with the mRNA amounts, was a poor prognostic
marker in lung carcinoma [17] and glioma [18]. Further-
more, Lv et al. suggested that cells with elevated midkine
mRNA were resistant to cisplatin treatments [17]. In
contrast, Wu et al. showed that midkine expression in-
creased susceptibility of epithelial ovarian cancer cells to
cisplatin/paclitaxel through down-regulated multidrug
resistance-associated protein 3 and indicated that prog-
nosis of the ovarian cancer patients with midkine-
positive tumor cells was better than those with midkine-
negative cells [34]. Extending tumor sizes due to the
rapid proliferative ability is in general a poor prognostic
factor but swift cell growth is also associated with in-
creased sensitivity to anti-cancer agents targeting DNA
replication and DNA damages. In clinical settings, many
factors can affect drug sensitivity in vivo, which include
genetic alterations of tumors such as those influencing
anti-apoptotic and pro-apoptotic pathways. In addition,
a serum concentration of proteins are regulated by a
glomerular filtration rate and a body mass index of re-
spective persons. These multiple factors in total reflect
data of patient survival periods, and the prognostic
values of a biomarker are subjected to an analyzing sys-
tem how the patients are divided into subgroups.
Conclusions
In conclusions, mesothelin is a useful biomarker with a
moderate sensitivity and a relatively high specificity for
the diagnosis of mesothelioma, but the level was not as-
sociated with the patient prognosis. In contrast, midkine
can differentiate mesothelioma only from benign asbes-
tos pleurisy but the base line level of midkine predicted
prognosis of mesothelioma patients. Midkine is thus a
novel biomarker for mesothelioma and has a different
clinical value from mesothelin.
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